Bioptimus hits major funding milestone, unveils plans for transformative biology model

Bioptimus, a Paris-based leader in artificial intelligence innovation, has reached a remarkable funding milestone of $76 million, underscoring its potential to transform biological research. The funding includes a recent $41 million investment led by Cathay Innovation, with additional support from Sofinnova Partners, Bpifrance’s Large Venture Fund, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, and angel investors Emmanuel Cassimatis and Thomas Wolf. These investments will bolster Bioptimus’s mission to deliver the world’s first universal AI foundation model for biology, a groundbreaking tool that promises to redefine how biological systems are studied and applied.

Leading AI-Driven Innovation in Biology

Bioptimus has rapidly established itself as a pioneer in the development of AI-driven models for biological research. Its latest innovation, the H-Optimus-0, represents the world’s largest foundation model for pathology and has already set a benchmark in the field. Released in July 2024, H-Optimus-0 has outperformed competing models in independent tests conducted by institutions such as Harvard Medical School and the University of Leeds. These evaluations demonstrated the model’s exceptional capacity to predict gene expression from morphological data and accurately subtype ovarian cancer, achieving results that were previously unattainable.

Building on this success, Bioptimus is now developing a multi-scale, multi-modal foundation model for biology, set for release in 2025. This new model aims to simulate biological processes at an unprecedented scale, integrating data across molecules, cells, tissues, and entire organisms. The ability to holistically analyse these systems is expected to revolutionise industries including pharmaceuticals, biotechnology, and cosmetics.

Breaking Down Barriers in Biological Research

For decades, biological research has been hindered by siloed methodologies, where studies often focus on individual components such as proteins, DNA, or cells. Even current AI models are limited by these constraints, restricting their capacity for cross-disciplinary insights. Bioptimus is addressing this challenge by creating a platform that synthesises data from diverse biological scales and modalities, offering a truly integrated view of how life systems function.

Jean-Philippe Vert, co-founder and CEO of Bioptimus, highlighted the transformative potential of this approach. He described the forthcoming model as a tool that will empower researchers to simulate complex biological processes, predict disease outcomes, and design therapies with unprecedented precision. Vert likened the innovation to a GPT model for biology, stating that instead of generating text, Bioptimus’s platform will enable the simulation and understanding of biological complexities at their core.

Catalysing Innovation Across Industries

The implications of Bioptimus’s AI foundation model extend far beyond the medical field. By integrating imaging, genetics, and other datasets into a unified platform, the technology has the potential to drive innovation across multiple sectors. For instance, in cosmetics, the model could be used to simulate how different compounds interact with human skin, leading to safer and more effective products. In pharmaceuticals, it offers the ability to design and test therapies virtually, significantly reducing the time and cost associated with drug development.

Cathay Innovation’s Jacky Abitbol remarked on the significance of Bioptimus’s achievements, noting the company’s rapid progress since its initial funding round. Abitbol highlighted how Bioptimus has not only launched the world’s largest AI pathology model but has also established a world-class team and a robust research infrastructure.

Driving Future Growth Through Strategic Investment

The recent funding will enable Bioptimus to enhance its platform by integrating more diverse datasets and expanding its capabilities in therapeutic areas. The company also aims to establish strategic collaborations with leading pharmaceutical and biotechnology firms, ensuring its innovations align with real-world challenges. Additionally, this investment will support efforts to scale operations and refine the models for broader application.

The continued backing of prominent investors reflects growing confidence in Bioptimus’s vision and its potential to lead the next wave of innovation in biological research. By creating tools that allow researchers to explore biology in its full complexity, Bioptimus is setting a new standard for the use of artificial intelligence in the life sciences.

A Vision for the Future

As the global healthcare and biotechnology landscapes evolve, the demand for integrated, AI-driven solutions is only expected to grow. Bioptimus’s approach to breaking down silos in biological research offers a glimpse into the future of science, where AI enables discoveries that were previously out of reach.

With its innovative platform, Bioptimus is not only addressing current challenges in biological research but also unlocking new opportunities across industries. By harnessing the power of artificial intelligence to simulate life systems, the company is poised to redefine the possibilities for medical research, biotechnology, and beyond.